University of Thessaly (UTH)
Ο ρόλος του vegf και του οξειδωτικού stress στην παθογένεια των αποφρακτικών και περιοριστικών νοσημάτων του πνεύμονα
Abstract
dc:descriptionVascular endothelial growth factor (VEGF) is a potent mediator of angiogenesis which has multiple effects in the lung development and physiology. VEGF is expressed in several parts of the lung and the pleura while it has been shown that changes in its expression play a significant role in the pathophysiology of the most common lung diseases. However, the exact role of VEGF in the lung is not clear yet as there is contradictory evidence that suggests either a protective or a harmful role. VEGF seems to work in a different manner depending on its amount, the location of its action and the situation of the lung tissue. The lung is the only organ of the human body which has the highest exposure to oxygen. Owing to its large surface area and blood supply, the lung is susceptible to oxidative injury by virtue of myriads of reactive forms of oxygen species and free radicals. The main oxidative factors that are observed in the lung are reactive oxygen species and reactive nitrogen species. Oxidative stress plays a major role in airway inflammation. Thus, it can participate in the development and progress of many lung diseases, mainly through oxidation of different biological molecules that lead in cell death and destruction of the lung parenchyma. The current study investigates the role of VEGF and oxidative stress in patients with systemic sclerosis with and without pulmonary arterial hypertension and in patients with Chronic Obstructive Pulmonary Disease (COPD) which are divided in two groups according to their clinical phenotype. The association between SS and PAH is well recognized. VEGF has been reported to play an important role in pulmonary hypertension. The aim of the first protocol was to examine the relationship between systolic pulmonary artery pressure, clinical and functional manifestations of the disease and serum VEGF levels in systemic sclerosis. Serum VEGF levels were measured in 40 patients with systemic sclerosis and 13 control subjects. All patients underwent clinical examination, pulmonary function tests and echocardiography. Serum VEGF levels were higher in systemic sclerosis patients with pulmonary arterial hypertension than in those without pulmonary arterial hypertension, while they did not differ between systemic sclerosis patients without pulmonary arterial hypertension and controls. Serum VEGF levels correlated to systolic pulmonary artery pressure, to diffusing capacity for carbon monoxide and to MRC dyspnea score. In multiple linear regression analysis, serum VEGF levels, MRC dyspnea score, and DLCO were independent predictors of systolic pulmonary artery pressure. The aim of the second protocol was to determine the impact of the presence of HRCT-confirmed emphysema on VEGF levels, markers of oxidative stress and other biomarkers in blood and EBC and on lung function
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papaioannou, Andrianna
- Παπαϊωάννου, Ανδριάνα
Subjects
dc:subject × 13- Αγγειακός ενδοθηλιακός αυξητικός παράγοντας (VEGF)
- Οξειδωτικό στρες
- Χρόνια αποφρακτική πνευμονοπάθεια (ΧΑΠ)
- Πνευμονική υπέρταση
- Φλεγμονές
- Λειτουργικός έλεγχος αναπνευστικού
- Ανάλυση μάζας σώματος
- Σκληρόδερμα
- VEGF ( Vascular endothelium growth factor)
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/18159